Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
finolimab
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Finolimab (QL1604) is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. Developed by Qilu Pharmaceutical, it acts as an immune checkpoint inhibitor by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade prevents the suppression of T-cell activity, thereby enhancing the immune system's ability to recognize and eliminate cancer cells. Finolimab is currently being investigated in several clinical trials, including a Phase II study at Sun Yat-Sen University Cancer Center for the neoadjuvant treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma in combination with paclitaxel and platinum. It has also reached Phase III development for cervical cancer in China.
- Brand names
- Anruize
- Other names
- finolimabQL-1604QL1604QL 1604
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on finolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on finolimab.